Connection

Co-Authors

This is a "connection" page, showing publications co-authored by GUILLERMINA LOZANO and SHUNBIN XIONG.
Connection Strength

4.368
  1. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. Cancer Res. 2022 05 16; 82(10):1926-1936.
    View in: PubMed
    Score: 0.875
  2. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol. 2017 03; 241(4):501-510.
    View in: PubMed
    Score: 0.604
  3. Developing genetically engineered mouse models to study tumor suppression. Curr Protoc Mouse Biol. 2012 Mar 01; 2(1):9-24.
    View in: PubMed
    Score: 0.431
  4. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3226-31.
    View in: PubMed
    Score: 0.284
  5. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv. 2024 Feb 16; 10(7):eadk1835.
    View in: PubMed
    Score: 0.247
  6. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discov. 2023 05 04; 13(5):1230-1249.
    View in: PubMed
    Score: 0.234
  7. Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. Proc Natl Acad Sci U S A. 2022 Nov 08; 119(45):e2210618119.
    View in: PubMed
    Score: 0.226
  8. Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo. Cancer Res. 2022 04 01; 82(7):1313-1320.
    View in: PubMed
    Score: 0.217
  9. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021 08; 11(8):2094-2111.
    View in: PubMed
    Score: 0.203
  10. Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proc Natl Acad Sci U S A. 2019 08 27; 116(35):17429-17437.
    View in: PubMed
    Score: 0.181
  11. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun. 2018 09 27; 9(1):3953.
    View in: PubMed
    Score: 0.170
  12. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes Dev. 2017 09 15; 31(18):1847-1857.
    View in: PubMed
    Score: 0.158
  13. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res. 2016 Jan; 14(1):56-65.
    View in: PubMed
    Score: 0.139
  14. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol. 2014 Aug; 233(4):380-91.
    View in: PubMed
    Score: 0.126
  15. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res. 2008 Nov 01; 68(21):8968-75.
    View in: PubMed
    Score: 0.086
  16. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol. 2007 Dec; 213(4):360-8.
    View in: PubMed
    Score: 0.080
  17. Wnt/?-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death Dis. 2021 05 21; 12(6):521.
    View in: PubMed
    Score: 0.051
  18. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19.
    View in: PubMed
    Score: 0.032
  19. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.